BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36533536)

  • 1. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues.
    Bian D; Zhao J; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2023 Apr; 30(4):303-309. PubMed ID: 36533536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients.
    Zhao J; Bian D; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
    Front Cell Infect Microbiol; 2023; 13():1083912. PubMed ID: 37065191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
    Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B.
    Chang XJ; Sun C; Chen Y; Li XD; Yu ZJ; Dong Z; Bai WL; Wang XD; Li ZQ; Chen D; Du WJ; Liao H; Jiang QY; Sun LJ; Li YY; Zhang CH; Xu DP; Chen YP; Li Q; Yang YP
    World J Gastroenterol; 2019 Aug; 25(32):4764-4778. PubMed ID: 31528100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
    Mak LY; Wong D; Kuchta A; Hilfiker M; Hamilton A; Chow N; Mao X; Seto WK; Yuen MF
    Clin Mol Hepatol; 2023 Jan; 29(1):146-162. PubMed ID: 35989092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients.
    Li J; Wu Z; Wang GQ; Zhao H
    Chin Med J (Engl); 2021 Mar; 134(10):1160-1167. PubMed ID: 33734135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.
    Wang Y; Liu Y; Liao H; Deng Z; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Chen X; Duan Z; Lu F; Zheng S
    Int J Med Sci; 2022; 19(5):858-866. PubMed ID: 35693741
    [No Abstract]   [Full Text] [Related]  

  • 11. [Analysis and significance of HBV DNA below the lower detection limit of HBV RNA levels after long-term NAs antiviral therapy in patients with hepatitis B virus cirrhosis].
    Wang CY; Cao Y; Feng YM; Li J; Jiang B; Zhang Y; Wen J; Zhu YJ; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):758-762. PubMed ID: 36038347
    [No Abstract]   [Full Text] [Related]  

  • 12. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
    Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
    Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
    Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
    Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
    Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
    J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
    Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
    Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy.
    Erken R; Zaaijer HL; Willemse SB; Bakker E; Takkenberg BB; Reesink HW; Kootstra NA
    Ann Hepatol; 2021 Dec; 26():100540. PubMed ID: 34583061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients.
    Zhang ZQ; Shi BS; Lu W; Liu DP; Huang D; Feng YL
    Gastroenterol Hepatol; 2020 Nov; 43(9):526-536. PubMed ID: 32921478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.